The company announced today that it has received official notification from the U.S. Patent and Trademark Office that it has been issued a key patent supporting its iSONEP program. The new patent claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet AMD (age-related macular degeneration). The company has a similar patent in Europe.
Lpath is currently conducting a Phase II clinical trial for iSONEP, called Nexus, which is evaluating the anti-S1P antibody’s safety and efficacy in wet-AMD patients. In 2010, the company entered into an agreement with drug giant Pfizer that provides Pfizer an exclusive option for worldwide license to develop and commercialize iSONEP.
The company is also conducting a Phase II trial for ASONEP in renal cell carcinoma patients. Both iSONEP and ASONEP are formulations of sonepcizumab, a first-in-class therapeutic antibody against S1Pdeveloped using Lpath’s ImmuneY2. Antibodies developed using this discovery engine are designed to target bioactive signaling lipids that are involved in cancer, macular degeneration, and many other diseases.
For further information about Lpath, its ImmuneY2 discovery engine, and its drug candidates, please visit www.Lpath.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
